# A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

> **NCT04810676** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 27 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** CKD-501, D745, D150
- **DRUG:** CKD-383

## Key facts

- **NCT ID:** NCT04810676
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-16
- **Primary completion:** 2021-05-20
- **Final completion:** 2021-05-26
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04810676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04810676, "A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04810676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*